© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
March 19, 2021
Most of the time, evidence of a cancer therapy’s success in clinical trials is reassuring. This time, it was not.
Major thrombosis is a significant danger for patients with MPN who become infected with COVID-19, and antithrombotic prophylaxis does not appear to eliminate the risk.
February 15, 2021
Expression or mutations in SAMHD1 does not appear to be linked with failure-free survival or complete remission rates in patients with mantle cell lymphoma who are treated with high-dose cytarabine-based chemotherapy.
January 25, 2021
A new meta-analysis confirms that ASXL1 mutations could be an important prognostic indicator in patients with myeloproliferative neoplasms.